Pfizer begins trial for omicron-specific COVID-19 vaccine – Boston 25 News

Health Security Agency found that boosters are 75% effective at preventing symptomatic infections from omicron two to three weeks after the booster was given, but that at 10 weeks, they weaken, providing only 45% to 50% protection against symptomatic infection, CNBC reported.

By using this website, you accept the terms of our Visitor Agreement and Privacy Policy, and understand your options regarding Ad Choices.

…Read the full story